In the BioHarmony Drug Report Database
Ocaliva (obeticholic acid) is a small molecule pharmaceutical. Obeticholic acid was first approved as Ocaliva on 2016-05-27. It is used to treat cholangitis in the USA. It has been approved in Europe to treat biliary liver cirrhosis. The pharmaceutical is active against bile acid receptor. In addition, it is known to target nuclear receptor coactivator 2. Ocaliva’s patents are valid until 2036-04-26 (FDA).
Image (chem structure or protein)